Startseite
Märkte
Charts & Ideen
Algo
Nachrichten
Store
Broker
Herunterladen
Wirtschaftskalender
Handelssignale
WebTerminal
Geben Sie
/
ein, um zu suchen: @user, $symbol
Suche
Einloggen
Eröffnen Sie ein Konto
Deutsch
English
Русский
中文
Español
Português
日本語
한국어
Français
Italiano
Türkçe
VTGN
#4002
Vistagen Therapeutics, Inc. Common Stock
0.607
3
USD
-3.73%
Sektor:
Gesundheitswesen
Basis:
USD
Gewinnwährung:
USD
Tagesspanne
Jahresspanne
Tagesänderung
-3.73%
Monatliche Änderung
+17.90%
6 month change
+17.90%
Jahresänderung
+17.90%
Vorheriger Schlusskurs
0.630
8
Open
0.607
3
Bid
0.607
3
Ask
0.610
3
Low
0.607
3
High
0.607
3
Volumen
6
Märkte
Aktien
Gesundheitswesen
VTGN
Open full chart
Financials
Overview
Finanzbericht
Statistics
Quarterly
Annual
Value
2020
2021
2022
2023
2024
TTM
Key stats
Total common shares outstanding
6.38 M
6.89 M
7.87 M
27.03 M
29.16 M
—
Valuation ratios
Enterprise value
—
—
—
26.74 M
5.76 M
74.42 M
Price to earnings ratio
—
—
—
-3.55
-1.5
-4.82
Price to sales ratio
—
—
—
98.23
158.83
443.43
Price to cash flow ratio
—
—
—
-4.05
-1.83
-5.63
Price to book ratio
—
—
—
0.91
1.1
1.81
Enterprise value to EBITDA ratio
—
—
—
—
—
—
Profitability ratios
Return on assets %
0.17
0.64
2.81
0.24
0.61
0.91
Return on equity %
0.19
0.74
4.9
0.26
0.73
1.12
Return on invested capital %
1 363.97
3 390.02
4 642.81
2 867.66
4 598.63
5 050.58
Gross margin %
100
100
100
100
100
400
Operating margin %
1 646.06
4 308.3
26.11 K
3 103.48
11.52 K
96.99 K
EBITDA margin %
—
—
—
—
—
—
Net margin %
1 646.09
4 306.76
26.1 K
2 759.59
10.58 K
91.71 K
Liquidity ratios
Quick ratio
—
—
—
—
—
—
Current ratio
24.85
12.32
3.83
23.55
6.51
22.95
Inventory turnover
—
—
—
—
—
—
Asset turnover
0.02
0.01
0
0.01
0
0.01
Solvency ratios
Debt to assets ratio
—
—
—
—
—
—
Debt to equity ratio
—
—
—
—
—
—
Long term debt to total assets ratio
0
—
—
0
—
—
Long term debt to total equity ratio
0
—
—
0
—
—
Per share metrics
Operating cash flow per share
—
-6.86
-7.14
1.33
1.36
1.72
EBIT per share
—
—
—
—
—
—
EBITDA per share
—
—
—
—
—
—
Total debt per share
—
—
—
—
—
—
Cash per share
—
10.32
2.39
6.16
2.61
8.21
Net current asset value per share
—
10.76
2.52
6.23
2.66
8.45
Tangible book value per share
—
9.81
1.74
5.9
2.28
7.12
Working capital per share
—
9.88
1.86
5.97
2.25
6.99
Book value per share
—
9.81
1.74
5.9
2.28
7.12
Nachrichten
Vistagen Therapeutics streicht 20 % der Stellen zur Kostensenkung
Vistagen Therapeutics reduces workforce by 20 percent to manage costs
VistaGen auf der TD Cowen Konferenz: Pherin-Plattform im Fokus
VistaGen at TD Cowen Conference: Pherine Platform in Focus
Vistagen Therapeutics: Verwaltungsratsmitglied Paul Edick tritt zurück
Vistagen Therapeutics, Inc. (VTGN) Q3 2026 Earnings Call Transcript
Earnings Call von VistaGen: KI-gestützte Analyse im Fokus der Q3-Ergebnisse 2026
Earnings call transcript: VistaGen Therapeutics Q3 2026 highlights AI-driven trial analysis
VistaGen Therapeutics, Inc. (VTGN) Reports Q3 Loss, Lags Revenue Estimates
Vistagen Therapeutics: Phase-3-Studie für Fasedienol verfehlt primären Endpunkt
Vistagen Therapeutics reports Phase 3 trial for fasedienol did not meet endpoint
U.S. stocks lower at close of trade; Dow Jones Industrial Average down 0.47%